NREP
NEW REPRESENTATIVE AT IB RECEIVED
30/07/2026
Voltar para busca
Dado oficial do USPTO
R
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
30/07/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
17/10/2016
Data de registro
04/07/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/01/2024
Última transação
30/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
CH
Examinador
MURRAY, DAVID T
Unidade examinadora
M40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a stylized letter "R" with a beaker design forming the left side of the letter "R".
Titulares e representantes
Titulares
RIVOPHARM S.A.
Representantes
Jeffrey B. Sladkus The Sladkus Law Group
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationsboth prescription and over-the-counterpharmaceutical preparations for peptic ulcer and gastrooesophageal reflux disease (GORD)propulsivesintestinal anti-infectivesintestinal anti-inflammatory agentsoral pharmaceutical preparations for lowering blood glucoseVitamin A and Dmixed vitamin preparations consisting of vitamins A and Dvitamin and mineral preparations for medical usevitamin C in the nature of ascorbic acid mixed vitamin preparations consisting partially of Vitamin Ccalcium supplementsmineral supplementsanti-thrombotic agentsintravenous solutionscardiac glycosidesclass I and class III anti-arrhythmicspharmaceutical preparations for cardiac stimulation excluding cardiac glycosidesVasodilators used in the treatment of cardiac diseasesanti-adrenergic agentspharmaceutical preparations for acting on arteriolar smooth muscleBeta blocking agentsSelective calcium channel blockerspharmaceutical preparations in the nature of Angiotensin Converting Enzyme inhibitorspharmaceutical preparations in the nature of Angiotensin Converting Enzyme inhibitors combined with other pharmaceutical preparationsanti-fungals for systemic useanti-infectives and antisepticsexcluding those combined with corticosteroidsoxytocicsplain corticosteroids for systemic usethyroid preparationsanti-thyroid preparationstetracyclines preparationsmacrolideslincosamides and streptograminsaminoglycoside antibacterialsquinolone antibacterialsantimycotics for systemic usedirect acting antiviralsimmune serabacterial vaccinesalkylating agentsanti-metabolitesplant alkaloidscytotoxic antibioticshormone antagonists and related agentsanti-estrogensanti-androgens and enzyme inhibitorsimmunosuppressive agentsantiinflammatory and antirheumatic preparationsnon-steroids in the nature of butylpyrazolidinesacetic acid derivativesoxicamspropionic acid derivativesfenamatesCoxibsmuscle relaxantsperipherally acting agents in the nature of curare alkaloids and choline derivativesantigout preparationsanalgesics and antipyretics preparationsanti-migraine preparationsanti-epileptic preparationsanti-cholinergic agentsdopaminergic agentsanti-psychoticsanxiolyticshypnotics and sedativesantidepressantsparasympathomimeticsagents for use against amoebiasis and other protozoal diseasesanti-malarial preparationadrenergicsinhalant anestheticsadrenergics for systemic useantihistamines for systemic usediuretic agents
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
17/11/2024
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
24/09/2024
INPC
INVALIDATION PROCESSED
24/09/2024
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
20/09/2024
C71T
CANCELLED SECTION 71
19/01/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
04/07/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/11/2017
GPNX
NOTIFICATION PROCESSED BY IB
13/10/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/10/2017
FIMP
FINAL DISPOSITION PROCESSED
05/10/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/10/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
04/07/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/04/2017
PUBO
PUBLISHED FOR OPPOSITION
18/04/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
29/03/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
29/03/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/03/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/03/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/03/2017
DMCC
DATA MODIFICATION COMPLETED
06/03/2017
ALIE
ASSIGNED TO LIE
03/03/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/03/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/03/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/03/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/03/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/03/2017
RFNT
REFUSAL PROCESSED BY IB
09/12/2016
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
15/11/2016
RFRR
REFUSAL PROCESSED BY MPU
15/11/2016
MAFR
APPLICATION FILING RECEIPT MAILED
11/11/2016
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/11/2016
CNRT
NON-FINAL ACTION WRITTEN
08/11/2016
DOCK
ASSIGNED TO EXAMINER
08/11/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/11/2016
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
03/11/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace R ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.